The Inquisitor: New setbacks leave Elan even more vulnerable
The firm has been hit by the failure of its latest Alzheimer drug trials, and the imminent departure of Kelly Martin as chief executive, writes Richard Curran.
Robert Ingram, the chairman of Elan, told shareholders last March that group chief executive Kelly Martin would be staying on until data from trials of its potential new Alzheimer's treatment Bapineuzumab were made available.
Ingram said the drug was potentially of "transformational significance" for the company. Last week's disappointing results, which saw it fail to get through clinical trials, may well end up being transformational for Elan, but not in the way Ingram had in...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
*New subscribers only
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team